Debiopharm strikes early to lock in rights to Chugai anticancer
This article was originally published in Scrip
Executive Summary
Chugai has licensed its early stage oncology candidate FF284 to Debiopharm globally, excluding Japan where the Roche Japanese affiliate retains rights.